Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte, Inc. has announced the commencement of two separate underwritten public offerings: one for $500 million of common stock and pre-funded warrants, and another for $500 million aggregate principal amount of convertible senior notes due 2032. The company intends to use the net proceeds from both offerings primarily to fund the clinical development of its VAX-31 adult and pediatric vaccine programs, support manufacturing scale-up, and invest in commercial preparations for VAX-31's anticipated U.S. launch. The offerings are subject to market conditions and each offering's completion is not contingent on the other.
Vaxcyte Announces Positive Phase 3 Results for VAX-31
Vaxcyte announced positive topline data from its pivotal OPUS-1 Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine. The trial successfully met all primary immunogenicity and safety endpoints compared to existing vaccines, demonstrating broad serotype coverage and a favorable safety profile. These results support a planned Biologics License Application and suggest VAX-31 could offer enhanced protection against pneumococcal disease in adults.
Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial
Vaxcyte's shares surged 50% after its VAX-31 vaccine candidate met all primary endpoints in the pivotal OPUS-1 Phase 3 trial. The vaccine demonstrated noninferiority and superiority against comparator vaccines for specific serotypes in adults aged 50 and older, with a favorable safety profile. The company anticipates additional Phase 3 results in 2027 and plans to submit a Biologics License Application for VAX-31 in early 2028.
Vaxcyte Stock Hits New 52-Week High - Here’s Why
Vaxcyte Inc. (NASDAQ: PCVX) stock surged by over 56% in premarket trading, reaching a new 52-week high after announcing positive topline results from its Phase 3 OPUS-1 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine. The vaccine met all primary immunogenicity endpoints, demonstrating noninferiority to existing vaccines from Pfizer and Merck, and showed a strong safety profile. These findings will support an upcoming Biologics License Application submission to the U.S. FDA, with further trial results expected in 2027.
S&P 500 Futures Decline in Premarket Trading; Vaxcyte, PTC Lead
S&P 500 futures saw a decline in premarket trading. Despite the overall market trend, Vaxcyte Inc. (PCVX) and PTC Inc. (PTC) experienced significant gains, rising 54.1% and 36.2% respectively. This indicates a mixed performance with some individual stocks bucking the broader market downturn.
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte, Inc. announced positive topline results from its OPUS-1 pivotal adult Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The study showed VAX-31 met all prespecified primary immunogenicity endpoints across age groups compared to existing vaccines, demonstrating a similar safety profile. These results will support a planned Biologics License Application, with further Phase 3 trial results expected in early 2027.
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Vaxcyte, Inc. announced positive topline results from its OPUS-1 pivotal adult Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified primary endpoints for safety, tolerability, and immunogenicity compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) in adults. These results will form the cornerstone of a planned Biologics License Application submission in the first half of 2028, with further Phase 3 trial results expected in the first half of 2027.
Trial data on a vaccine designed to prevent bacterial pneumonia are set for Oct. 5. Vaxcyte will present them.
Vaxcyte (PCVX) is scheduled to host a webcast and conference call on October 5, 2026, at 8:00 a.m. ET / 5:00 a.m. PT to unveil topline data from its OPUS-1 Phase 3 adult trial. The trial evaluates the safety, tolerability, and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate aimed at preventing invasive pneumococcal disease and pneumococcal pneumonia. The company's pipeline includes several other vaccine candidates, leveraging its XpressCF® cell-free protein synthesis platform.
Vaxcyte to present phase 3 trial data for vaccine candidate
Vaxcyte, Inc. announced it will host a conference call on Monday at 8:00 a.m. ET to present topline data from its OPUS-1 adult pivotal Phase 3 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The trial evaluated VAX-31's safety, tolerability, and immunogenicity to prevent invasive pneumococcal disease and pneumonia. Vaxcyte's pipeline also includes VAX-24, VAX-XL, VAX-A1 for Group A Strep, and VAX-GI for Shigella prevention, utilizing its XpressCF cell-free protein synthesis platform.
Vaxcyte EVP Jim Wassil Executes Stock Option and Sells Shares via Rule 10b5-1 Plan
Vaxcyte EVP, Chief Scientific Officer, and COO Jim Wassil exercised 2,250 stock options at $5.35 per share on October 1, 2026, and subsequently sold all acquired shares in two transactions on the same day. The sales were conducted under a Rule 10b5-1 trading plan established on December 9, 2025. After these transactions, Wassil directly owns 145,435 shares and holds 64,398 exercisable stock options.
A 2,250-share sale is proposed by Vaxcyte (PCVX) officer James Wassil.
Vaxcyte officer James Wassil has proposed selling 2,250 common shares of Vaxcyte (PCVX), valued at approximately $127,642.50, with an approximate sale date of October 1, 2026. The shares were acquired through the exercise of a stock option with a cash payment. The filing also notes several earlier sales made by Wassil in July, August, and September 2026.
InvestingPro predicted Vaxcyte’s 49% decline two years ago By Investing.com
InvestingPro's Fair Value analysis accurately predicted a 49% decline in Vaxcyte's stock price two years ago. In September 2024, despite a market surge, the analysis flagged PCVX as significantly overvalued due to negative financial fundamentals. This case highlights how intrinsic valuation methods can help investors identify mispricing and make informed decisions, demonstrating the value of systematic analysis for avoiding overvalued situations.
Current ratio of Vaxcyte, Inc. – HAN:5VA
The article focuses on the current ratio of Vaxcyte, Inc. (HAN:5VA), a biotechnology company listed on the Hannover Stock Exchange. It highlights where to find this financial data within the TradingView platform, emphasizing that the information is provided by ICE Data Services and FactSet.
Enterprise value to revenue forward of Vaxcyte, Inc. – HAN:5VA
The article presents the "Enterprise value to revenue forward" metric for Vaxcyte, Inc. (HAN:5VA) on the Hannover Stock Exchange. It indicates that the market is currently closed with no trades. The content primarily focuses on financial data for the company.
Total common shares outstanding of Vaxcyte, Inc. – HAN:5VA
This article provides data on the total common shares outstanding for Vaxcyte, Inc. (HAN:5VA) on the Hannover Stock Exchange. It notes that the market was closed with no trades. The content also lists various financial and community features available on the platform.
Vaxcyte Price Target Cut to $130.00/Share From $133.00 by B of A Securities
B of A Securities has lowered its price target for Vaxcyte (NASDAQ:PCVX) to $130.00 per share, down from the previous target of $133.00. The firm maintained a "Buy" rating on the stock. This adjustment reflects a revised outlook on the company's valuation while still recommending a purchase.
PCVX Maintains Buy Rating -- Price Target Lowered to $130 by B o
B of A Securities analyst Jason Gerberry maintained a "Buy" rating for Vaxcyte (PCVX) but lowered the price target from $133.00 to $130.00. Vaxcyte is a clinical-stage vaccine company focusing on bacterial infections, with a current share price of $57.54, significantly below the new target. The company has a low GF Score™ of 40/100, reflecting weak profitability and growth, despite strong financial health, and has seen notable insider selling.
BofA Securities Adjusts Vaxcyte Price Target to $130 From $133, Maintains Buy Rating
BofA Securities has revised its price target for Vaxcyte (PCVX) shares, lowering it to $130 from the previous $133, while reiterating a Buy rating on the stock. The adjustment was reported on September 28, 2026, at 07:49 am EDT. Vaxcyte is a clinical-stage vaccine company focusing on bacterial diseases with a pipeline including VAX-31 and VAX-24 candidates.
Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History
This article provides comprehensive financial information for Vaxcyte, Inc. (PCVX), including its current stock price, recent performance metrics, key financial data, and analyst insights. It details the company's overview as a clinical-stage vaccine innovation company, its lead vaccine candidates, and its market position in the biotechnology sector.
PCVX: Vaxcyte Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Vaxcyte Inc. (PCVX), including its current stock price, market capitalization, and key financial metrics. It highlights recent company news, such as the appointment of new senior executives and updated timelines for its VAX-31 pneumococcal vaccine program's Phase 3 data. The piece also includes market sentiment and trading ideas from analysts regarding PCVX stock.
Vaxcyte (PCVX) Could Be 71% Below Fair Value Following A Valuation Split
Vaxcyte (PCVX) is currently trading at a significant discount to its estimated fair value of $202.46 per share, despite recent share price momentum cooling. While its Price-to-Book ratio of 3.1x appears good value against peers, it's higher than the broader US biotech sector average, reflecting the market's pricing of its future projects over current earnings. The company, an early-stage vaccine developer, reported a substantial loss and minimal revenue, making its valuation dependent on successful clinical trials and future intellectual property.
Vaxcyte (PCVX) officer plans stock sale after RSU vest
Vaxcyte, Inc. officer James Wassil has filed a Form 144 indicating a proposed sale of 1,334 common shares, valued at approximately $80,026.66, following an RSU vest on September 7, 2026. This filing also details several prior sales of Vaxcyte common stock by Wassil in the preceding three months. The transactions are being handled by UBS Financial Services Inc.
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com
Jim Wassil, EVP, CSO, and COO of Vaxcyte, Inc. (NASDAQ:PCVX), sold a total of 2,715 shares of company stock worth $163,862 through multiple transactions between September 4 and September 9, 2026. These sales were executed under a Rule 10b5-1 trading plan. Wassil also surrendered 5,459 shares to cover tax obligations from vested restricted stock units, and now directly holds 145,435 shares.
Vaxcyte EVP Jim Wassil sells $163,862 in company stock
Vaxcyte Executive Vice President Jim Wassil sold 2,715 shares of Vaxcyte, Inc. stock for a total of $163,862 through pre-arranged trading plans between September 4 and September 9, 2026. Additionally, Wassil surrendered 5,459 shares to cover tax withholding obligations. These transactions come as Vaxcyte shares have seen an 82% increase over the past year, though InvestingPro analysis suggests the stock is currently overvalued.
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
Vaxcyte's CFO, Andrew Guggenhime, disposed of 2,705 shares worth approximately $165,492 to cover tax withholding obligations on vested restricted stock units. This transaction was not a discretionary sale, and Guggenhime still retains a substantial stake in the company, valued at over $10 million. Despite a significant half-year net loss of $604.9 million, Vaxcyte maintains a strong cash position of $2.51 billion, which the company states will support its clinical, manufacturing, and commercial-readiness milestones.
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm
Vaxcyte's CEO, Grant Pickering, sold 6,289 shares of common stock in a non-discretionary transaction to cover tax withholding obligations from restricted stock unit vesting. The biotechnology company is focused on its lead candidate VAX-24, a pneumococcal conjugate vaccine, and is awaiting pivotal Phase 3 trial data for VAX-31 in the fourth quarter. While the company has seen a 95% share price increase over the last year, it also reported a significant cash burn, highlighting the importance of upcoming trial results for its future trajectory.
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades
Vaxcyte officer James Wassil has filed a Rule 144 notice to sell 1,381 shares of common stock, valued at approximately $82,487.13 as of September 4, 2026. This proposed sale follows several other insider sales by Wassil in July, August, and September 2026, totaling over $460,000. The shares to be sold were acquired through an RSU vest on September 2, 2026, and the transaction will be processed through UBS Financial Services Inc.
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ)
Vaxcyte has narrowed the timing for the release of topline results from its pivotal Phase 3 trial of pneumococcal vaccine candidate VAX-31 to late October, an update from its previous fourth-quarter guidance. These OPUS-1 results, which will include safety and tolerability data, are critical for potential regulatory submission and for VAX-31 to compete with existing vaccines, as it aims to protect against 31 bacterial serotypes. The company has also appointed experienced leaders to bolster its clinical, regulatory, and commercialization strategies for the vaccine.
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble
Vaxcyte (PCVX), a clinical-stage vaccine maker, is nearing critical data readouts for its lead pneumococcal vaccine candidate, VAX-31, with results from its primary Phase 3 trial (OPUS-1) expected in Q4 2026. The company is investing heavily in R&D, leading to increased net losses, but holds significant cash reserves. The outcome of these trials will be pivotal for its future, as the market shows skepticism with decreased hedge fund ownership and high short interest.
Vaxcyte appoints two executives, narrows trial timeline
Vaxcyte Inc. (NASDAQ: PCVX) announced the appointment of Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. The company also narrowed the timeline for its VAX-31 adult Phase 3 OPUS-1 trial results, now expected by the end of October 2026, and anticipates data from OPUS-2 and OPUS-3 in the first half of 2027. VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate being evaluated for invasive pneumococcal disease and pneumonia.
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte (Nasdaq: PCVX) has announced the appointments of Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer. The company also narrowed its guidance for the expected topline safety, tolerability, and immunogenicity data from its VAX-31 adult Phase 3 OPUS-1 trial, now anticipating results by the end of October 2026. These strategic appointments and the updated timeline for key clinical data mark a pivotal period for Vaxcyte as it progresses towards potential commercialization of VAX-31.
Vaxcyte stock jumps on new executives, VAX-31 data timeline
Vaxcyte Inc. (NASDAQ:PCVX) shares rose by 6.3% in after-hours trading following the announcement of two senior leadership appointments and a narrowed timeline for its VAX-31 vaccine trial data. Luis Jodar was named Chief Medical Officer and David McAvoy as Chief Legal Officer. The company now expects topline data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October 2026, and data from OPUS-2 and OPUS-3 in the first half of 2027.
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte, Inc. announced the appointments of Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer. The company also narrowed its guidance for the expected topline safety, tolerability, and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial, now anticipating results by the end of October 2026. These leadership additions and updated timelines underscore Vaxcyte's progress towards potential commercialization of VAX-31.
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte, Inc. has announced the appointments of Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer, bringing extensive experience in vaccine development and legal leadership to the company. Concurrently, Vaxcyte has narrowed its guidance for the expected topline safety, tolerability, and immunogenicity data from its VAX-31 adult Phase 3 OPUS-1 pivotal trial, now anticipated by the end of October 2026. These strategic personnel additions and the updated trial timeline position Vaxcyte for the potential commercialization of its VAX-31 vaccine candidate.
Vaxcyte COO Jim Wassil sells over $212,000 in company stock
Vaxcyte's COO, Jim Wassil, sold 3,477 shares of company stock for over $212,000 through a Rule 10b5-1 trading plan, while also exercising stock options and surrendering shares for tax obligations. Despite the sales, Wassil still directly owns 153,609 shares. The transactions occurred as Vaxcyte's stock trades near its 52-week high and is considered overvalued by InvestingPro analysis, even as the company announced changes to its board of directors.
Former Pfizer vaccine chief joins Vaxcyte. Trial data is expected by October’s end.
Vaxcyte has appointed Luis Jodar, former Pfizer vaccine chief, as its Chief Medical Officer and David McAvoy as Chief Legal Officer. The company also narrowed its guidance for the VAX-31 adult Phase 3 OPUS-1 topline data readout, now expecting results by the end of October 2026. These appointments and the upcoming data are critical as Vaxcyte prepares for potential commercialization of its VAX-31 vaccine candidate.
Vaxcyte COO Jim Wassil sells over $212,000 in company stock
Jim Wassil, COO of Vaxcyte Inc. (NASDAQ:PCVX), sold 3,477 shares worth over $212,000 via a Rule 10b5-1 trading plan, while also exercising stock options and surrendering shares for tax obligations. These transactions occur as Vaxcyte stock trades near its 52-week high, with InvestingPro analysis suggesting it is overvalued. Separately, Vaxcyte announced board changes, with Jacks Lee retiring and Moncef Slaoui being appointed as a new independent director.
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. (Nasdaq: PCVX) announced its management will participate in investor conferences. The clinical-stage vaccine innovation company will host one-on-one meetings and fireside chats. This engagement provides an opportunity for investors to learn more about the company's progress and future plans.
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left
Seth Klarman's Baupost Group has fully exited its position in Vaxcyte (PCVX) as of Q2 2026, a move mirrored by other institutions but countered by some increasing their stakes. Vaxcyte, a clinical-stage biotech, faces a significant binary catalyst with Phase 3 data for its VAX-31 vaccine expected in Q4 2026, but the stock is currently overbought despite a strong uptrend. This complex scenario, coupled with recent insider selling, makes the upcoming trial results critical for PCVX's future trajectory.
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone
Seth Klarman's Baupost Group completely exited its positions in Vaxcyte (NASDAQ:PCVX) and Willis Towers Watson (NASDAQ:WTW) during the second quarter of 2026, selling 800,000 and 893,126 shares respectively. This move was disclosed in a 13F filing on August 13, 2026, meaning retail investors who mimicked Klarman's Q1 filings would have bought into positions he had already abandoned. The article highlights the risk for retail investors following stale 13F filings, especially with pre-catalyst stocks like Vaxcyte, which faces a binary event with its OPUS-1 Phase 3 trial results in Q4 2026.
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative
Vaxcyte (PCVX) recently reported expanded Q2 2026 net losses of US$284.3 million and higher basic loss per share, alongside a first-half loss of US$604.92 million. Despite the losses, the company announced full enrollment in its three pivotal VAX-31 adult Phase 3 trials and early progress for VAX-A1, indicating significant investment in its vaccine pipeline. Completing enrollment in the VAX-31 trials is seen as a key milestone, positioning Vaxcyte closer to a biologics license application and shifting focus to upcoming data readouts, which will determine if current investments support the long-term thesis amidst rising cash burn concerns.
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative
Vaxcyte (PCVX) recently reported expanded Q2 2026 losses and a higher basic loss per share, alongside the significant milestone of fully enrolling three pivotal VAX-31 adult Phase 3 trials. This progress reinforces the company's focus on its vaccine pipeline, with the completion of VAX-31 enrollment being a key near-term catalyst. Investors are now looking towards the upcoming OPUS-1 Phase 3 data readouts to assess if current heavy investments will support the long-term thesis, amidst concerns about increasing cash burn.
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research
Zacks Research has upgraded Vaxcyte (NASDAQ:PCVX) from a "strong sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $86. The company recently reported a quarterly loss of $1.97 per share, outperforming estimates. Insider selling and institutional ownership figures were also detailed.
(PCVX) Movement as an Input in Quant Signal Sets
This article analyzes Vaxcyte Inc. (NASDAQ: PCVX) using AI models to generate trading strategies. It highlights a near-term strong sentiment influencing mid-term neutrality towards a long-term positive bias, noting that resistance is being tested. The analysis provides specific entry and target points for long, breakout, and short strategies based on different risk profiles and time horizons.
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX
Assenagon Asset Management S.A. significantly reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 91.3% in the second quarter, selling over 1 million shares and retaining 101,433 shares valued at approximately $5.9 million. Despite this, institutional investors still hold 96.78% of the company's stock. The article also notes mixed analyst ratings, recent insider stock sales totaling $6.57 million, and Vaxcyte's recent earnings report where it beat EPS estimates.
Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake
Janus Henderson Group Ltd. has disclosed a significant ownership stake in Vaxcyte, Inc. (PCVX), reporting beneficial ownership of 18,040,375 common shares, which represents 12.1% of the outstanding stock as of July 31, 2026. This stake is held through various affiliated asset managers in client accounts known as Managed Portfolios, which exercise shared voting and dispositive power. No single Managed Portfolio owns more than five percent of Vaxcyte's common stock, and the Managed Portfolios are entitled to all dividends and sale proceeds.
Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline
Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing novel vaccines for bacterial infectious diseases, with a strong pipeline including VAX-24. Despite being unprofitable with a negative P/E and EPS, analysts project an 87.70% upside with an average target price of $109.00, driven by the potential of its innovative vaccine candidates. The stock is trading above its 50-day and 200-day moving averages, indicating technical strength, and holds a balanced RSI of 56.73.
Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients
Janus Henderson Group Ltd. filed an amended Schedule 13G, disclosing beneficial ownership of 65,694 shares of Vaxcyte, Inc. common stock, representing a 0.1% stake. These shares are held through its asset management subsidiaries for client accounts, where Janus Henderson has shared voting and dispositive power but no sole control. The Managed Portfolios retain rights to dividends and sale proceeds, with no single portfolio owning more than 5% of Vaxcyte.
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX
The Manufacturers Life Insurance Company reduced its stake in Vaxcyte, Inc. by 20.4% in Q1 2026, selling 22,079 shares but retaining 86,366 shares valued at $5.0 million. Despite this, institutional ownership remains high at 96.8%, with several other major funds increasing their positions. Vaxcyte's shares opened at $58.89, and while the company beat its quarterly loss estimate, analysts anticipate continued losses as it progresses through upcoming vaccine trial catalysts.
Vaxcyte (PCVX) Is Up 8.9% After Completing VAX-31 Phase 3 Enrollment Amid Rising Losses – Has The Bull Case Changed?
Vaxcyte (PCVX) recently reported increased net losses in Q2 2026 but saw its stock rise after completing Phase 3 enrollment for its VAX-31 vaccine. This significant progress in clinical trials, alongside the VAX-A1 study, is critical for the company's future, as investors weigh these advancements against rising costs and the need to manage its cash runway. Analysts are watching for the OPUS-1 adult data as the next key catalyst, with some optimistic projections for revenue and fair value despite current losses.
